Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/47633
Title: Evaluation of Outcomes of Peritoneal Dialysis Patients in the Post-COVID-19 Period: A National Multicenter Case-Control Study from Turkey
Authors: Ozturk S.
Gursu M.
Arici M.
Sahin I.
Eren N.
Yilmaz M.
Koyuncu S.
Karahisar Sirali, Semahat
Ural, Zeynep
Dursun, Belda
Yuksel, Enver
Uzun, Sami
Sipahi, Savas
Ahbap, Elbis
Yazici, Halil
Altunoren, Orcun
Tunca, Onur
Ayar, Yavuz
Gok Oguz, Ebru
Kahvecioglu, Serdar
Asicioglu, Ebru
Oruc, Aysegul
Ataman, Rezzan
Aydin, Zeki
Huddam, Bulent
Dolarslan, Murside Esra
Azak, Alper
Bakirdogen, Serkan
Yalcin, Ahmet Ugur
Karadag, Serhat
Ulu, Memnune Sena
Gungor, Ozkan
Ari Bakir, Elif
Odabas, Ali Riza
Seyahi, Nurhan
Yildiz, Alaattin
Ates, Kenan
Keywords: Complication
COVID-19
Outcome
Peritoneal dialysis
Publisher: S. Karger AG
Abstract: Introduction: There are not enough data on the post-CO-VID-19 period for peritoneal dialysis (PD) patients affected from COVID-19. We aimed to compare the clinical and laboratory data of PD patients after COVID-19 with a control PD group. Methods: This study, supported by the Turkish Society of Nephrology, is a national, multicenter retrospective case-control study involving adult PD patients with confirmed COVID-19, using data collected from April 21, 2021, to June 11, 2021. A control PD group was also formed from each PD unit, from patients with similar characteristics but without COVID-19. Patients in the active period of COVID-19 were not included. Data at the end of the first month and within the first 90 days, as well as other outcomes, including mortality, were investigated. Results: A total of 223 patients (COVID-19 group: 113, control group: 110) from 27 centers were included. The duration of PD in both groups was similar (median [IQR]: 3.0 [1.88-6.0] years and 3.0 [2.0-5.6]), but the patient age in the COVID-19 group was lower than that in the control group (50 [IQR: 40-57] years and 56 [IQR: 46-64] years, p < 0.001). PD characteristics and baseline laboratory data were similar in both groups, except serum albumin and hemoglobin levels on day 28, which were significantly lower in the COVID-19 group. In the COVID-19 group, respiratory symptoms, rehospitalization, lower respiratory tract infection, change in PD modality, UF failure, and hypervolemia were significantly higher on the 28th day. There was no significant difference in laboratory parameters at day 90. Only 1 (0.9%) patient in the COVID-19 group died within 90 days. There was no death in the control group. Respiratory symptoms, malnutrition, and hypervolemia were significantly higher at day 90 in the COVID-19 group. Conclusion: Mortality in the first 90 days after COVID-19 in PD patients with COVID-19 was not different from the control PD group. However, some patients continued to experience significant problems, especially respiratory system symptoms, malnutrition, and hypervolemia. © 2022 S. Karger AG, Basel. Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
URI: https://doi.org/10.1159/000526234
https://hdl.handle.net/11499/47633
ISSN: 1660-8151
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
Evaluation of Outcomes.pdf269.57 kBAdobe PDFView/Open
Show full item record



CORE Recommender

SCOPUSTM   
Citations

3
checked on Oct 13, 2024

WEB OF SCIENCETM
Citations

2
checked on Oct 31, 2024

Page view(s)

64
checked on Aug 24, 2024

Download(s)

16
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.